An Open-label Phase 2 Study to Evaluate the Safety and Immnogenicity of a Single Subcutaneous Injection of Quadrivalent TAK-850 in Healthy Adult Subjects
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2016
At a glance
- Drugs TAK 850 (Primary)
- Indications Influenza A virus infections; Influenza B virus infections; Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Takeda
- 24 Aug 2016 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 22 Apr 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 22 Mar 2016 New trial record